Curis Inc (NAS:CRIS)
$ 3.96 -0.18 (-4.35%) Market Cap: 35.05 Mil Enterprise Value: 15.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Curis Inc Virtual KOL Event - Reviewing CA-4948 Clinical Data in NHL & AML/MDS Transcript

Dec 08, 2020 / 01:00PM GMT
Release Date Price: $131 (+354.86%)
James E. Dentzer
Curis, Inc. - President, CEO & Director

Good morning everyone, and welcome to our Virtual Key Opinion Leader call to discuss clinical data on our first-in-class IRAK4 inhibitor, CA-4948. 12 months ago, we outlined our goals for 2020 to provide data updates from both of our ongoing clinical trials of CA-4948. Today, we're excited to provide these updates.

For the NHL study, in a presentation yesterday at ASH, we formally identified our recommended Phase II dose, which has demonstrated tumor reduction in 6 of 7 patients and robust tolerability up to 2 years. All of this in single-agent therapy in a heavily pretreated patient population. These are patients who enrolled in our study after feeling on average 4 prior lines of treatment with other therapies.

In addition, we are especially excited about the identification of 2 new biomarkers, which we expect will help us with patient selection and enrichment as we advance into the combination study of CA-4948 with ibrutinib.

For the AML and MDS study, we are highly encouraged by the data released an hour ago.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot